The neuropathological assessment of amyloid in brain parenchyma (CERAD score) and vasculature (CAA) as well as tau accumulation (Braak staging) in the brain guided the classification of cases as neurologically healthy controls (Emory: N=20; UPenn: N=25) or Alzheimer’s disease (Emory: 61; UPenn: N=12). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.